| Message from the CEO
Welcome to Lantheus Medical Imaging and thank you for taking the time to learn more about our company. As a worldwide leader in diagnostic imaging for the past 50 years, we remain committed to our customers and patients and making important investments to continue to elevate the field of medical imaging. We are excited about the future of our company as we expand on our proud heritage of providing innovative diagnostic imaging products that illuminate the heart and other organs. We encourage you to learn more about Lantheus Medical Imaging, our people, products and pipeline.
Lantheus Updates
Molybdenum-99 Supply Statement from Lantheus Medical Imaging
As a Technetium-99m (Tc-99m) generator manufacturer, we are one part of a very complex supply chain. We are working with our suppliers to obtain Molybdenum-99 (Mo-99) during this current shortage. The amount of Mo-99 we receive over the course of this outage will vary day by day. read more
|
|
News
01/20/10
LANTHEUS MEDICAL IMAGING, INC. LAUNCHES ABLAVAR™ (GADOFOSVESET TRISODIUM), A NEW DIAGNOSTIC MAGNETIC RESONANCE ANGIOGRAPHY AGENT
10/8/09
DATA FEATURING GADOFOSVESET TRISODIUM, THE FIRST AND ONLY MRA BLOOD POOL AGENT
APPROVED IN THE U.S., PRESENTED AT
MRA-CLUB 09: 21ST ANNUAL INTERNATIONAL CONFERENCE ON MAGNETIC RESONANCE ANGIOGRAPHY
9/17/09
LANTHEUS MEDICAL IMAGING, INC. INITIATES PHASE 1 STUDY EVALUATING SAFETY AND DOSIMETRY OF NOVEL HEART FAILURE IMAGING AGENT
8/14/09
LANTHEUS CONTINUES TO ADDRESS INDUSTRY SHORTAGE OF Mo-99
RESULTING FROM PROLONGED NRU REACTOR SHUTDOWN
|
|
Company Spotlight
Lantheus Medical Imaging, Inc. Launches ABLAVAR™ (Gadofosveset Trisodium),
a New Diagnostic Magnetic Resonance Angiography Agent
ABLAVAR™ is the First and Only Contrast Imaging Agent Approved for Use With Magnetic Resonance Angiography (MRA) in the United States
N. BILLERICA, Mass. (January 20, 2010) – Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the launch of ABLAVAR™ (gadofosveset trisodium), a unique, injectable MRA imaging agent used to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD). ABLAVAR™ is the first and only contrast imaging agent approved in the United States for use with a magnetic resonance angiography (MRA) indication to evaluate AIOD. AIOD is a type of PVD that occurs when arteries, which carry blood from the heart to the lower limbs, become narrowed or blocked. This lack of blood supply can result in pain, infection and even loss of limbs1.
click here for the press release
|
